Menadione sodium bisulfite is screened through a 500 µm sieve before direct compression. The trihydrate contains approximately 52% w/w menadione activity, and this assay basis drives the low-dose tablet formula. A 10 mg menadione activity tablet requires 19.2 mg of the trihydrate equivalent. Direct compression blends are prepared in a 50 L bin blender at 15 rpm for 20 minutes. Microcrystalline cellulose PH102 and lactose monohydrate are pre-blended for 3 minutes. Crospovidone is added at 4.0% w/w to support disintegration below 15 minutes per USP 701. Magnesium stearate is limited to 0.5% w/w because overlubrication reduces tablet hardness from 120 N to below 60 N on a 10-station rotary press. Blend uniformity is verified by HPLC with acceptance value not more than 15.0 per USP 905. Tablet tensile strength is maintained above 1.5 MPa at a main compression force of 15 kN. The processing room is held at 35% relative humidity because menadione sodium bisulfite picks up moisture above 60% RH and causes sticking on concave tooling. A white opaque HPMC coating at 3.0% w/w weight gain is applied in a 24-inch pan with inlet air at 45°C. The coating reduces photolytic degradation but does not eliminate the need for aluminium/aluminium blister packaging.

What Limits Terminal Sterilization of Phytonadione Veterinary Injectables?

Phytonadione injectable emulsions are heat-sensitive. Terminal steam sterilisation at 121°C for 15 minutes can reduce droplet zeta potential below 20 mV, leading to creaming. Aseptic filtration through 0.22 µm polyethersulfone membranes is therefore preferred. The aqueous vehicle contains soybean oil, phospholipid emulsifier, and polysorbate 80. Pressure homogenisation at 500 bar produces a mean droplet diameter below 300 nm. Droplet size is measured by laser diffraction. pH is adjusted to 5.0–7.0 with acetate buffer. Nitrogen overlay reduces headspace oxygen below 2.0% v/v. Sodium metabisulfite is added at 0.1% w/v as an oxygen scavenger, but sulfite-sensitive species require labelling. USP 71 sterility testing and USP 788 particulate matter at ≥10 µm and ≥25 µm apply. The small-volume injectable limit is 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Bacterial endotoxin is controlled below 0.5 EU/mg per USP 85. Process hold time for bulk emulsion after homogenisation is limited to 8 hours at 15–25°C because droplet coalescence accelerates above 25°C. Propylene glycol above 50% w/w increases viscosity beyond 50 mPa·s and slows sterile filtration.

In water-soluble powder production, the critical processing boundary is the dew point of the fluid-bed inlet air. Menadione sodium bisulfite is dissolved in purified water at 40°C. The solution is sprayed at 15% of dry-bed mass per hour onto lactose monohydrate. Inlet air dew point is held below 5°C. Product temperature is maintained at 30°C. A top-spray fluid-bed granulator with 0.8 mm nozzle orifice and atomising air pressure of 2.5 bar produces agglomerates with D50 180–250 µm. Povidone K30 is used as binder at 2.0% w/w in the spray solution. Karl Fischer moisture per USP 921 is controlled below 2.0% w/w. Water activity below 0.40 prevents caking. Sieve analysis per USP 786 requires not less than 90% of material between 75 µm and 400 µm. Residual solvents are checked per USP 467. The granulated powder is filled into multi-layer foil-lined bags. High humidity above 60% RH during packaging causes particle fusion and reduces flowability below 4 g/s through a 10-mm orifice. Trace iron above 20 ppm from stainless steel contact surfaces accelerates oxidative degradation. Product is stored at 15–25°C.

Capsule Fill Parameters in Low-Dose Vitamin K3 Encapsulation

Hard gelatin capsules require a powder bed density above 0.65 g/cm³ for consistent dosing disc fill at 60,000 capsules per hour. Menadione sodium bisulfite is pre-blended with mannitol and pregelatinized starch to reach a final API concentration of 5.0 mg per size 3 capsule. Colloidal silicon dioxide at 0.2% w/w improves flow. Magnesium stearate is omitted because capsule lubrication is provided by plug ejection force. Addition above 0.1% w/w slows dissolution. Fill weight variation is tested per USP 905. In-process capsule weight is checked by automatic checkweigher with rejection limits of ±3.0%. Shell moisture is held between 13.0% and 16.0% w/w per USP 731. Processing below 35% RH causes shell embrittlement. Processing above 55% RH causes capsule softening and API hydrolysis. Dissolution is run per USP 711 using Apparatus 2 at 50 rpm. After 30 minutes, not less than 80% of label claim is typical for gelatin capsules. Light-accelerated degradation requires amber HDPE bottles with desiccant canisters. Long-term stability under ICH Q1A at 25°C/60% RH and accelerated 40°C/75% RH defines shelf-life.

When Menadione Sodium Bisulfite Premix Encounters Trace-Metal and Choline Chloride Stress

Because premix manufacture exposes vitamin K activity to reactive inorganic carriers, the carrier selection is a stability decision as much as a dilution step. Calcium carbonate carriers contain free iron and copper at trace levels. Menadione sodium bisulfite degrades rapidly when redox-active metal content exceeds 50 ppm total. The degradation pathway involves sulfite oxidation and menadione ring opening. In a 2000 kg ribbon blender, the premix is made as a 1.0% w/w menadione activity intermediate on corn cob fractions. Choline chloride 60% carrier grade introduces free water up to 2.0% w/w and is excluded from the initial blend. When choline chloride is necessary, menadione nicotinamide bisulfite or menadione dimethylpyrimidinol bisulfite is used instead of MSB. The vitamin K activity is classified under Regulation (EC) No 1831/2003 as a nutritional additive in the functional group of vitamins and provitamins. The premix is discharged by gravity into paper bags with polyethylene liner. Dust control is achieved by adding 0.3% w/w food-grade mineral oil after the active blend has reached uniformity. Mixing time is set at 20 minutes. Sampling uses a slot thief at 10 points. Coefficient of variation after mixing is below 5.0%. The premix is labelled with a maximum carry-over rate of 1.0 kg per tonne of complete feed to avoid exceeding target vitamin K activity. Published data for this specific formulation configuration is limited, but the incompatibility trend is documented in feed additive stability literature.

In oral solution manufacture, vitamin K3 solubility is pH-dependent. Menadione sodium bisulfite dissolves freely in water at not less than 10 g/L. The solution is buffered with 0.05 M citrate to pH 5.0. Above pH 7.5, menadione precipitates and the solution darkens from pale yellow to amber. Sodium metabisulfite at 0.05% w/v maintains reducing conditions but can react with sodium benzoate preservative at acid pH. A mixed preservative system of methylparaben 0.18% w/v and propylparaben 0.02% w/v is used. Polysorbate 80 at 0.5% w/v prevents adsorption of menadione to linear low-density polyethylene containers. The batch is manufactured in a 500 L jacketed stainless tank with bottom-mounted mixer at 150 rpm. Nitrogen sparging reduces dissolved oxygen below 1.0 mg/L before filling. Filling is performed into amber PET bottles. Headspace oxygen is kept below 3.0% v/v. The solution is filtered through a 0.45 µm polyvinylidene fluoride cartridge before filling. Viscosity remains below 10 mPa·s at 25°C, which ensures low fill-weight variation on a 12-head volumetric filler. Microbial limits follow USP 1111. Label claim is verified by HPLC with acceptance 90.0–110.0% of declared vitamin K activity.

A granulation line exposed to choline chloride requires moisture and pH controls before letdown.

Dry granulation with roller compaction is used when choline chloride is added before final mixing. Menadione sodium bisulfite is compacted with microcrystalline cellulose and croscarmellose sodium. Roller pressure is set at 30 bar. Produced ribbons are milled through a 1.0 mm screen. A moisture specification of not more than 1.5% w/w is imposed before choline chloride addition. Choline chloride 60% carrier form carries free water up to 2.0% w/w. Mixing wet choline chloride carrier with MSB drives hydrolysis. The granule pH is measured as a 10% aqueous slurry with a target below 6.0. pH above 7.0 triggers degradation and ammonia-like odour. The process therefore separates choline chloride into a post-granulation blend. This sequenced addition reduces interaction area. Finished granules are screened through 850 µm and filled into anti-static polyethylene-lined kraft bags. Free-flowing granules are used in oral dosing powders and feed top dress applications.

Photostability of vitamin K veterinary dosage forms under ICH Q1B influences packaging decisions. Menadione and phytonadione absorb in the UV range. Tablets, capsules, and powders packaged in clear HDPE fail to meet label claim after 30 days of near-UV exposure. A confirmatory study under ICH Q1B uses a xenon lamp with an integrated near-UV irradiance of not less than 200 W·h/m² and visible light of 1.2 million lux·h. Liquid formulations in amber glass with UV cutoff below 450 nm show acceptable retention. Solid dosage forms in aluminium/aluminium blisters show no spectral degradation after 6 months at 25°C/60% RH. The packaging specification includes opacity and light transmission limits measured by spectrophotometry. Carton labels state protect from light per compendial monograph.